Scrutinize the data and tweets to envisage if the closing price of $amgn will swell or contract at 2017-03-23. Please affirm either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-03-09,-0.5,0.1,-1.0,0.6,0.6,-0.1,-0.7,-1.5,-2.7,-3.7,-5.3
2017-03-10,-1.1,0.3,-1.3,1.4,1.4,-1.3,-1.7,-2.6,-3.6,-4.6,-6.1
2017-03-13,0.5,0.5,-0.4,-0.2,-0.2,-1.0,-1.2,-2.1,-3.0,-4.0,-5.4
2017-03-14,0.2,0.8,-0.3,-0.5,-0.5,-0.1,-0.5,-1.3,-2.2,-3.2,-4.5
2017-03-15,-1.3,0.9,-1.3,1.4,1.4,-1.0,-1.6,-2.3,-3.1,-4.2,-5.3
2017-03-16,0.8,1.0,-1.2,-1.4,-1.4,0.5,-0.1,-0.7,-1.5,-2.5,-3.6
2017-03-17,-0.7,1.8,-1.6,-6.4,-6.4,5.9,6.0,5.8,5.1,4.2,3.2
2017-03-20,0.2,0.3,-0.9,0.4,0.4,4.1,5.0,5.2,4.6,3.8,2.9
2017-03-21,1.9,2.0,-0.2,-1.4,-1.4,4.0,5.9,6.3,5.9,5.3,4.4
2017-03-22,0.3,0.3,-0.5,0.4,0.4,1.8,4.9,5.5,5.4,4.9,4.1

2017-03-09: rt AT_USER $spx #52weekhighs drop w/the market this week. $xlv getting healthier. #topdownthermometer #investools #ripbig #trendtr¡­|rt AT_USER $spx #52weekhighs drop w/the market this week. $xlv gett
2017-03-10: $amgn new trend line about 185 atm|$amgn futher rise in the trend is signaled could see 200-210+ in 90 days support AT_USER 177 175|why valeant $vrx $agn $myl $mrk $jnj $snap $twtr $fb $aapl $iep $gil
2017-03-11: rt AT_USER $spx #52weekhighs drop w/the market this week. $xlv getting healthier. #topdownthermometer #investools #ripbig #trendtr¡­|rt AT_USER $amgn $espr $mdco repatha outcome data next friday,  &gt
2017-03-12: benzinga: your guide to patent play exposure  $aapl $amgn $regn $sny $bbry $qcom $prkr $rpxc $spex $nok $tasr $dgly|your guide to patent play exposure  $aapl $amgn $regn $sny $bbry $qcom $prkr $rpxc $
2017-03-13: $amgn:us rpt-data on heart benefits of amgen drug is key to unlocking sales #amgen inc   #nasdaq|$amgn:us rpt-data on heart benefits of amgen drug is key to unlocking sales #amgen inc   #sp500|looking
2017-03-14: $amgn steers #pcsk9 blockbuster hopeful through another promising phiii, but the critical test is looming  $sny|$amgn: analyst action by ubs on amgen: |$amgn max pain is 175.00 for maturity 03/17/2017
2017-03-15: rt AT_USER ahead of the #acc17 fourier presentation, here's an interview i did w/harvard pilgrim on repatha risk sharing. |$amgn:us mizuho analysts give amgen, inc. (amgn) a $195.00 price target #amge
2017-03-16: AT_USER $amgn news is on their cholesterol drug, re: cv benefits|rt AT_USER nice job rbc surveying 100 cardiologist on cholesterol lowering drugs   10 key takeaways $amgn $regn $mrk $espr $mdco |get t
2017-03-17: $amgn max pain is 175.00 for maturity 03/24/2017. prev close = 180.11.   |#amgen and axt slump while adobe and tiffany advance. read more:  $amgn|$amgn - amgen's repatha study shows reduced risk of he
2017-03-18: $amgn sum put vol=7,803 sum call vol=5,079 putcallratio=1.54 expiration 03/24/2017 .  |bharara was investigating hhs chief tom price - report $amgn $bmy $lly $pfe $aet  via AT_USER|u can be lay and in
2017-03-19: rt AT_USER week in review: bgi genomics plans $250 million shenzhen ipo $pfe $amgn |#amgen discounts cholesterol drug, but payers want more. read more:  $amgn|rt AT_USER $amgn says 11 million american
2017-03-20: member video: #1358 $vrx $memp $nktr $amgn nails &amp; good 'ol $espr making me try all day  |the #acc17 skinny: amgen's pcsk9 outcry, az's sglt2 death cuts, xarelto's aspirin beat  $amgn $azn|rt AT_U
2017-03-21: AT_USER yea thats a good point would need to be someone big though ie like $kite $amgn $june $celg etc|rt AT_USER just posted my thoughts on the fourier trial data with repatha:  $amgn $espr $sny $reg
2017-03-22: rt AT_USER $ibb $xbi $celg $agn $amgn $regn $gild can't stress the importance of this video enough! $study |$ibb $xbi $celg $agn $amgn $regn $gild can't stress the importance of this video enough! $st
Answer:
Fall